Literature DB >> 15330725

Evaluation and review of pharmacoeconomic models.

Joel W Hay1.   

Abstract

Difficult decisions as to whether to provide or withhold drug therapy to patients are needed to be made on a daily basis. These decisions should be based on carefully designed and constructed pharmacoeconomic models, with explicit and justifiable parameter values, validated by publication in peer-reviewed literature. This review describes and evaluates the common types of pharmacoeconomic models, modelling approaches and methods. It also discusses model quality, validity and usefulness.

Entities:  

Mesh:

Year:  2004        PMID: 15330725     DOI: 10.1517/14656566.5.9.1867

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

Review 1.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

2.  Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model.

Authors:  Jack Brown; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.

Authors:  Lihua Zhang; Joel W Hay
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.

Authors:  James R Spalding; Joel Hay
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.

Authors:  Xinke Zhang; Joel W Hay; Xiaoli Niu
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

6.  The use of mechanistic evidence in drug approval.

Authors:  Jeffrey K Aronson; Adam La Caze; Michael P Kelly; Veli-Pekka Parkkinen; Jon Williamson
Journal:  J Eval Clin Pract       Date:  2018-06-11       Impact factor: 2.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.